Avadel Pharmaceuticals plc announced the appointments of Courtney Wells as Vice-President, Clinical Operations and David Seiden, MD, FAASM as Senior Medical Director. As Vice-President Clinical Operations, Ms. Wells will lead all of Avadel’s clinical operations activities for FT218, including oversight of the company's Phase 3 REST-ON study. She joins Avadel from Levo Therapeutics, where she served as Vice President Clinical Operations, and was a key contributor in developing and overseeing clinical studies for this rare disease company. Previously, she was Vice President Clinical Operations at AveXis Inc., where she directed and oversaw the Company’s clinical research initiatives for the first gene therapy product approved in neurology by the FDA. Prior to joining AveXis, Ms. Wells was a Senior Program Manager at Marathon Pharmaceuticals, where she led two clinical programs including planning, oversight, and execution of all compound-related clinical studies from protocol writing through site identification/feasibility, recruitment and enrollment completion, and generation of clinical study reports. Additionally, she has held clinical research and operations positions at Abbott, PPD, Novartis, Abraxis Bioscience, Sanofi and Astellas Pharma. She holds a Bachelor of Science in Biochemistry and Molecular Biology from the University of Arizona. Ms. Wells has worked on multiple successful new drug applications in her career as well as built out multiple clinical operations departments. As Senior Medical Director, Dr. Seiden, a board-certified neurologist/sleep specialist and recognized expert in sleep medicine, will oversee clinical trials and lead all Medical Affairs and publication-related efforts related to Avadel’s lead asset, FT218. He has more than 20 years of experience in Neurology and Sleep Medicine and has been a Principal Investigator and pharmaceutical consultant for over 100 sleep disorder clinical trials.